


FY 2025 Highlights

"In 2025, Ipsen delivered strong sales and profit growth and continued to execute across all three TAs with a notable performance from Iqirvo."



David Loew
Chief Executive Officer



Geographic Breakdown

Total sales by region: 2025






North America
35%
of total sales

Europe
40%
of total sales

RoW
25%
of total sales

In this map, Europe is defined as the E.U., the U.K., Iceland, Liechtenstein, Norway, and Switzerland.



2025 Regulatory Highlights

Tovorafenib: EMA regulatory submission

Cabometyx®: EU approval in NETs

IPN10200: Proof-of-concept data readout in aesthetics

2026 Guidance²

Total sales growth: >13.0% at CER¹

Core operating margin: >35.0% of total sales

Henry Wheeler
Vice President
Investor Relations
+33 7 64 47 11 49
henry.wheeler@ipsen.com

Khalid Deojee
Senior Manager
Investor Relations
+33 6 66 01 95 26
khalid.deojee@ipsen.com